BioPharma Today

Latest News From "The Pink Sheet" DAILY - Avandia May Remain On Market With New Warnings, REMS

Avandia Can Be Saved With New Warnings and REMS, Advisory Cmte. Says

Latest News from "The Pink Sheet" DAILY - Cephalon Looks For Growth As Nuvigil Fails Schizophrenia Trial

Arena Gets Financing Boost, Lorcaserin Advisory Committee Date

Deerfield takes a $35.5 million equity stake, but finding a commercialization partner is still Arena's focus as it prepares for the September 16 panel review of its obesity drug.   read more

Latest News From "The Pink Sheet" DAILY - FDA Committee May Support Narrow Use Of Rezield

AstraZeneca's Rezield Might Itself Be Saved By Sicker Patients

Coming in Monday's "The Pink Sheet" DAILY - Genentech Gets Warning Letter for Rituxan Promotion

HHS establishes Office of Consumer Information and Insurance Oversight, headed by former Missouri insurance commissioner Jay Angoff, to manage private insurance reforms under health reform law.

Latest News from "The Pink Sheet" DAILY - Icahn Tries To Rain On Genzyme's Investor Day Parade

Advisory Panelists' Experience Carries Weight In Acthar Debate

FDA's Peripheral and Central Nervous System Drugs Advisory Committee members cite their own use of the drug in voting that Acthar Gel is effective at treating infantile spasms.   read more

Coming in Wednesday's "The Pink Sheet" DAILY - Merck, Pfizer Report Q1 Earnings

Acura and King plan to submit an NDA for a version of their oxycodone formulation Acurox that contains impediments to abuse by snorting or injection but does not contain the niacin FDA says is ineffective at preventing oral abuse.

Latest News from "The Pink Sheet" DAILY - Dendreon Set To Ship Provenge Soon

Dendreon Set To Ship Provenge Within A Week

Demand expected to exceed supply as company builds manufacturing capacity.   read more

Latest News From "The Pink Sheet" DAILY - Glaxo Unimpeded By Health Care Reform

Merck Names Ken Frazier President

Latest News from "The Pink Sheet" DAILY - Merck Puffs Up Respiratory Portfolio, Gets EU Rights To Nycomed's Daxas

New MannKind Data Appear Positive, But Doubts Persist About Afrezza's Viability

Pulmonary function data don't resolve questions about safety, analysts argue.   read more

Latest New from "The Pink Sheet" DAILY - King/Acura's Acurox Gets FDA Avisory Review

Alimera Raises $72 Million In IPO; Clips Share Price To $11 From Initial $15-$17 Range

$15 million will be used to pay debt to Australian drug maker pSivida, which gave Alimera its lead compound.   read more